Methods for detecting levels of pigment epithelium-derived factor and antithrombin-III for characterising and/or prognosing prostate cancer
AssigneeUniversity College Dublin, National University of Ireland
InventorsStephen Pennington, Brendan Murphy, William Watson
Life of this patent
Estimating the term…
Abstract
A method is provided for characterising and/or prognosing prostate cancer in a subject comprising measuring the level of at least one protein from a panel or at least one peptide thereof in a sample from the subject. The method may be used to determine the grade and stage of the prostate cancer. Also disclosed is a method for selecting a treatment for prostate cancer, together with corresponding methods of treatment. Systems and computing devices for performing the methods are also provided.
Claims13
A method comprising detecting levels of peptides in a biological sample from a subject, the peptides comprising:
- (i) a peptide of Pigment epithelium-derived factor having an amino acid sequence TVQAVLTVPK (SEQ ID NO:41);
- and
- (ii) a peptide of Antithrombin-III having an amino acid sequence TSDQIHFFFAK (SEQ ID NO:8),
- wherein the method further comprises:
- (i) comparing the level of the peptide of Pigment epithelium-derived factor to the level of the peptide of Pigment epithelium-derived factor in one or more control samples;
- and
- (ii) comparing the level of the peptide of Antithrombin-III to the level of the peptide of Antithrombin-III in one or more control samples,
- wherein the one or more control samples are from:
- (i) one or more subjects with extra-capsular extension of prostate cancer;
- (ii) one or more subjects with Gleason score 6 prostate cancer and/or Gleason score 7 prostate cancer;
- or
- (iii) one or more subjects with Gleason score 3+4 prostate cancer and/or Gleason score 4+3 prostate cancer.
A method comprising detecting levels in a biological sample of Pigment epithelium-derived factor, Antithrombin-III, Zinc alpha-2 glycoprotein, and Plasminogen, or at least one peptide thereof respectively, wherein the levels are measured by performing mass spectrometry comprising multiple reaction monitoring (MRM), wherein the biological sample comprises, consists essentially of or consists of:
- (a) a blood sample, optionally wherein the blood sample is a serum sample;
- (b) seminal fluid;
- (c) urine obtained after a prostatic massage;
- or
- (d) prostate tissue.
A method comprising:
- (a) detecting levels of Pigment epithelium-derived factor and Antithrombin-III, or at least one peptide thereof respectively, in a biological sample from a subject;
- and
- (b) after detecting levels of Pigment epithelium-derived factor and Antithrombin-III, or at least one peptide thereof respectively, in the biological sample from the subject, treating the subject with a therapy selected from hormone therapy that reduces the level and/or activity of testosterone in the subject, radiation, and radical prostatectomy.
A method comprising detecting levels in a biological sample of Pigment epithelium-derived factor, Antithrombin-III, and Zinc alpha-2 glycoprotein, or at least one peptide thereof respectively, wherein the levels are measured by performing mass spectrometry comprising multiple reaction monitoring (MRM), wherein the biological sample comprises, consists essentially of, or consists of:
- (a) a blood sample, optionally wherein the blood sample is a serum sample;
- (b) seminal fluid;
- (c) urine obtained after a prostatic massage;
- or
- (d) prostate tissue;
- wherein the method further comprises:
- comparing the level of Pigment epithelium-derived factor, or at least one peptide thereof, to the level of Pigment epithelium-derived factor, or at least one peptide thereof, in one or more control samples;
- and comparing the level of Antithrombin-III, or at least one peptide thereof, to the level of Antithrombin-III, or at least one peptide thereof, in one or more control samples;
- and comparing the level of Zinc alpha-2 glycoprotein, or at least one peptide thereof, to the level of Zinc alpha-2 glycoprotein, or at least one peptide thereof, in one of more control samples;
- wherein the one or more control samples are from:
- (a) one or more subjects with extra-capsular extension of prostate cancer;
- (b) one or more subjects with Gleason score 6 prostate cancer and/or Gleason score 7 prostate cancer;
- or
- (c) one or more subjects with Gleason score 3+4 prostate cancer and/or Gleason score 4+3 prostate cancer.
Dependencies are inferred from the claim text.